Trial reportRevista da Escola de Enfermagem da U S P2025
Effects of intravenous laser irradiation on viral load and T lymphocytes in people living with HIV/AIDS.
Trial report in Revista da Escola de Enfermagem da U S P, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effectiveness of intravenous laser irradiation of blood in reducing viral load and increasing LT-CD4+ and LT-CD8+ in people living with HIV/AIDS.
methodRandomized, controlled, parallel, single-blind clinical trial. Twenty-eight participants were allocated to the intervention (ILIB n = 15) and control (CTRL n = 13) groups. The ILIB group received irradiation with red laser (660 nm), applied to the radial artery (30 minutes/day for 20 days), with a total energy of 180 J. The CTRL group received a sham intervention (without light emission). Viral load and LT-CD4+ and LT-CD8+ counts were assessed at the end.
resultsBoth groups showed a reduction in viral load (ILIB: -1.7 log; CTRL: -2.3 log). In the ILIB group, 61.5% of participants achieved an undetectable viral load (p = 0.449). There was no increase in CD4+ LT count (p = 0.287), but a non-significant reduction in CD8+ LT count was observed in the ILIB group (p = 0.173). There were no statistically significant differences between groups for any outcome (p > 0.17). The study was stopped prematurely during the interim analysis.
conclusionILIB, as an adjuvant therapy to ART, did not show clinical or statistical superiority in the immunological and virological parameters evaluated. BRAZILIAN REGISTRY OF CLINICAL TRIALS (REBEC): RBR-7j9rv5d (https://ensaiosclinicos.gov.br/trial/10848).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.